{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:09:26Z","timestamp":1790885366555,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2003,5,19]],"date-time":"2003-05-19T00:00:00Z","timestamp":1053302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Imatinib mesylate is a selective tyrosine kinase inhibitor of c\u2010abl, bcr\/abl, c\u2010kit, and platelet\u2010derived growth factor\u2010receptor (PDGF\u2010R). c\u2010kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors investigated the efficacy of imatinib in patients with these disorders. Forty\u2010eight patients with AML (<jats:italic>n<\/jats:italic> = 10), MDS (<jats:italic>n<\/jats:italic> = 8), myelofibrosis (<jats:italic>n<\/jats:italic> = 18), atypical chronic myeloid leukemia (CML; <jats:italic>n<\/jats:italic> = 7), chronic myelomonocytic leukemia (CMML; <jats:italic>n<\/jats:italic> = 3), or polycythemia vera (<jats:italic>n<\/jats:italic> = 2) were treated with imatinib 400 mg daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>None of the patients with AML or MDS responded. Among patients with myelofibrosis, 10 of 14 patients with splenomegaly (71%) had a 30% or greater reduction in spleen size, 1 patient had trilineage hematologic improvement, 2 had erythroid hematologic improvement, and 1 had improvement in platelet count. One patient with atypical CML had erythroid hematologic improvement. Both patients with polycythemia vera needed fewer phlebotomies (from 2\u20133 per year to none during the 8 months of therapy and from 3\u20136 per year to 1 during 9 months of therapy). None of the three patients with CMML responded. Treatment was well tolerated. The side effects were similar to those observed in patients with CML.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Within these small subgroups of disease types, single\u2010agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF\u2010R fusion genes. Preliminary data on polycythemia vera are promising and deserve further investigation. Responses among myelofibrosis patients were minor. Therefore, a combination treatment regimen including imatinib may be more effective. Cancer 2003;97:2760\u20136. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.0000<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11416","type":"journal-article","created":{"date-parts":[[2003,5,21]],"date-time":"2003-05-21T06:01:27Z","timestamp":1053496887000},"page":"2760-2766","source":"Crossref","is-referenced-by-count":87,"title":["Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high\u2010risk myelodysplastic syndrome, and myeloproliferative disorders"],"prefix":"10.1002","volume":"97","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Letvak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Salvado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,5,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_5_3_2","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR\u2010ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR\u2010ABL protein by a tyrosine kinase inhibitor (CGP\u201057148)","volume":"4","author":"Beran M","year":"1998","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_2_5_11_2","first-page":"2167","article-title":"Treatment of Philadelphia chromosome\u2013positive, accelerated\u2010phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian HM","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.4947"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.925"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.596"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/106.2.192"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.7.2330.2330"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204844"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402556"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1985"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.813"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.325"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.577"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1999.00488.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1741"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3559"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057652"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.60.60"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1998.tb01042.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909083383"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(98)80037-1"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0154"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02918.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402596"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1182\/blood.V91.12.4419","article-title":"Fusion of Huntingtin interacting protein 1 to platelet\u2010derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)","volume":"91","author":"Ross TS","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3910"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2518"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0165"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_5_43_2","first-page":"273b","article-title":"Gleevec (imatinib mesylate) in 16 patients with chronic myelomonocytic leukemia (CMMoL)","volume":"98","author":"Raza A","year":"2001","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11416","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:45:46Z","timestamp":1760258746000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,19]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1002\/cncr.11416"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11416","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,19]]}}}